吡柔比星联合阿糖胞苷治疗急性髓系白血病28例疗效分析

Efficacy analysis of pirarubicin combined with cytarabine in the treatment of 28 patients with acute myeloid leukemia

目的观察以吡柔比星联合阿糖胞苷(TA)的化疗方案对急性髓系白血病的疗效。方法设吡柔比星联合阿糖胞苷的TA方案为治疗组,柔红霉素联合阿糖胞苷的DA方案为对照组,观察并评价1个或2个疗程后完全缓解(CR)率、总体反应(RR)率及不良反应。结果 2组完全缓解率和总有效率无统计学差异。治疗组支持治疗过程中使用G-CSF次数高于对照组。红细胞、血小板平均输注量高于对照组。非造血系统毒副作用:2组差异无统计学意义;造血系统毒副作用:仅粒缺持续时间治疗组明显高于对照组。结论 TA方案治疗急性髓系白血病与标准DA方案疗效相当,但TA方案对心脏毒性小于DA方案,可以作为DA方案替代方案用于急性髓系白血病一线治疗。

Objective To observe the efficacy of pirarubicin and cytarabine （TA） combined with chemotherapy for acute myeloid leukemia. Methods The treatment group received piraru- bicin combined with cytarabine （TA program） and the control group received daunorubicin com- bined with cytarabine （DA program）. The complete remission （CR） rate, overall response rate （RR） and adverse reactions were observed and evaluated after one or two cycles. Results CR rate and overall efficiency showed no significant difference. The number of patients using G-CSF in the treatment group was higher than that in the control group. Average transfusions of red blood cells and platelets were higher in the treatment group than in the control group in the course of treat- ment. No statistically significant difference was observed between the two groups in term of non- hematologic toxic effects. Only neutropenia duration of the treatment group was significantly higher than that in control group with regard to hematopoietic system side effects. Conclusion TA pro- gram is as effective as standard DA in the treatment of acute myeloid leukemia, but TA program for cardiac toxicity is less effective than the DA program, and it can be used as an alternative to DA pro- gram for the first-line treatment of acute myeloid leukemia.